Healionics- TR BioSurgical agreement for Glaucoma implant
Healionics Corporation has entered into a multi-year agreement in manufacturing, supply and distribution with TR BioSurgical, for use of its flagship STAR™ biomaterial scaffold in TRBIO’s TR-ClarifEYE, an implant used for treating glaucoma in animals. This implant will be out in market on a limited basis in early 2009. It relieves the elevated ocular pressure by trying to restore outflow of intraocular fluid from the anterior chamber of the eye to the surrounding vascular network. Healionics’ proprietary STAR (Sphere Templated Angiogenic Regeneration) supports the healing of implanted medical devices.
- Allergan-Asterand agreement for compounds
- New treatments challenging current gold standard treatment for glaucoma
- New technology will detect glaucoma earlier
- CE approves IOPtima noninvasive treatment of glaucoma
